公开(公告)号：US11160785B2

公开(公告)日：2021-11-02

申请号：US14776378

申请日：2014-03-14

申请人： AgeneBio, Inc.

发明人： Gardiner Smith

IPC分类号： A61K31/4015 ,  A61K31/445 ,  A61K31/27 ,  A61K31/662 ,  A61K31/55

摘要： The invention relates to compositions comprising a synaptic vesicle glycoprotein 2A (SV2A) inhibitor in an extended release and an acetylcholinesterase inhibitor (AChEIs). The invention also relates to using such compositions in treating cognitive impairment associated with central nervous system disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism, compulsive behavior, and substance addiction.

公开(公告)号：US20160271108A1

公开(公告)日：2016-09-22

申请号：US14776378

申请日：2014-03-14

申请人： AGENEBIO INC.

发明人： Gardiner Smith

IPC分类号： A61K31/4015 ,  A61K31/445

CPC分类号： A61K31/4015 ,  A61K31/27 ,  A61K31/445 ,  A61K31/55 ,  A61K31/662 ,  A61K2300/00

摘要： The invention relates to compositions comprising a synaptic vesicle glycoprotein 2A (SV2A) inhibitor in an extended release and an acetylcholinesterase inhibitor (AChEIs). The invention also relates to using such compositions in treating cognitive impairment associated with central nervous system disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism, compulsive behavior, and substance addiction.

摘要翻译： 本发明涉及包含延长释放的突触小泡糖蛋白2A（SV2A）抑制剂和乙酰胆碱酯酶抑制剂（AChEI））的组合物。 本发明还涉及使用这样的组合物治疗有需要或有风险的受试者的中枢神经系统疾病相关的认知障碍，包括但不限于具有年龄相关认知障碍或轻度认知障碍（MCI）的风险的受试者 ），痴呆，阿尔茨海默病（AD），前驱性AD，创伤后应激障碍（PTSD），精神分裂症，双相情感障碍，肌萎缩性侧索硬化（ALS），癌症治疗相关认知障碍，精神发育迟滞，帕金森病（PD） 自闭症，强迫行为和物质成瘾。